source
- Amgen’s Horizon-acquired drug dazodalibep meets primary endpoint in phase 3 Sjögren’s trialAmgen announced that its investigational fusion protein dazodalibep, acquired through Horizon Therapeutics, achieved its primary goal in a phase 3 study of patients with moderate to severe Sjögren’…
- Vertex reports positive Phase 2b results for inaxaplin in APOL1-mediated kidney diseaseVertex Pharmaceuticals announced positive Phase 2b data for its kidney disease candidate inaxaplin, which targets APOL1-mediated kidney disease (AMKD). The Amplified trial enrolled two cohorts: 2…